Report: Price for blindness gene therapy Luxturna is ‘four times too high’ at $850000 – Genetic Literacy Project
Genetic Literacy Project |
Report: Price for blindness gene therapy Luxturna is ‘four times too high’ at $850000
Genetic Literacy Project The report from the Institute for Clinical and Economic Review focused on the medicine Luxturna, the first-of-its-kind gene therapy approved for the U.S. market and the most expensive medicine by list price. It is the latest flashpoint in the debate … At $850000, price for new childhood blindness gene therapy four times too high, analysis saysPharmacy Today, American Pharmacists Association, pharmacist.com 6 amazing medical advancements to expect in 2018CNBC Spark Therapeutics: Challenges Posed By SuccessSeeking Alpha |
PharmaTimes |
Speedy EU, US review for Novartis’ CAR–T therapy Kymriah
PharmaTimes Regulators on both sides of the Atlantic are undertaking speedy reviews of Novartis’ CAR–T therapy Kymriah as a treatment for some patients with elapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). In the US, the Food and Drug … Novartis’s Kymriah wins speedy reviews in US, EuropeWHTC Novartis granted US FDA Priority Review for Kymriah™ (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCLMarkets Insider |